Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder

NCT04108104 is registered in ClinicalTrials.gov with Kinnov Therapeutics as lead sponsor.

NCT NCT04108104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04108104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder
Lead sponsor
Kinnov Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2019
Completion date
January 31, 2022
Enrollment
154 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder